Vice President & Managing Director,
Roel Bulthuis is Vice President and Managing Director of MS Ventures
, the strategic corporate venture capital arm of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.
In his role he is managing with his team a fund volume of €140 million with currently approximately 20 companies in the portfolio of MS Ventures. Being responsible for one of the most active and visible corporate venture funds in the biotech industry, he has the strategic mandate to invests in companies that develop products and/ or technologies that could benefit patients in therapeutic areas relevant to the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.
Roel Bulthuis joined the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in 2006 and started MS Ventures in 2009.
Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York.
Before joining Fortis Bank, Roel worked at Devgen NV in Gent, Belgium, as a business analyst.
Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.